arrow
R

Richard T. Maziarz

oregon health science university
H指数:86
被引数:3.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

免疫效应细胞相关神经毒性综合征的预测因素和结局:接受嵌合抗原受体T细胞治疗侵袭性B细胞非霍奇金淋巴瘤患者的分析

2026-10-210
OAAI
Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis

CD19嵌合抗原受体T细胞疗法后出现的迟发性血细胞减少:细胞治疗联盟的分析

2026-06-260
OA
Real World Clinical Outcomes in Melanoma Patients Treated at a Single-Center Tumor Infiltrating Lymphocyte (TIL) Therapy Program using commercial Lifileucel.

单中心肿瘤浸润淋巴细胞(TIL)疗法项目使用商业化Lifileucel治疗黑色素瘤患者的真实世界临床结局

2026-04-250
PRE
Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models

CD19-CAR-T治疗失败后的弥漫大B细胞淋巴瘤:更新后的真实世界结局、预后因素和预测模型

Blood
IF23.1
2025-12-010
PRE
Impact of ABO Compatibility on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT): Increased Risk of Acute GVHD with ABO Bidirectional Mismatch, Independent of Traditional and Emerging GVHD Prophylaxis Strategies

ABO配型对异基因造血干细胞移植(HCT)后结局的影响:ABO双向不合增加急性移植物抗宿主病(GVHD)的风险,且独立于传统和新兴的GVHD预防策略。

2025-11-170
PRE
Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

嵌合抗原受体T细胞疗法治疗高级别B细胞淋巴瘤NOS

2025-07-220
PRE
A model of lymphocryptovirus-associated post-transplant lymphoproliferative disorder in immunosuppressed Mauritian cynomolgus macaques
2024-11-111
OAAI
PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

PTPN11基因突变与接受表观遗传药物(包括低甲基化剂和Venetoclax)治疗的急性髓系白血病患者生存期缩短相关。

BLOOD
IF23.1
2024-11-050
PRE
Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia

社会决定因素对急性髓系白血病患者获得造血干细胞移植的影响

BLOOD
IF23.1
2024-11-050
PRE
Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry

tisagenlecleucel在复发/难治性滤泡性淋巴瘤患者中的疗效与安全性:来自血液与骨髓移植研究中心(CIBMTR)登记研究的真实世界分析

BLOOD
IF23.1
2024-11-050
PRE
Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents plus Venetoclax in Newly Diagnosed AML

免疫表型标志物CD7和CD56可改善一线低甲基化药物联合Venetoclax在初诊AML中的风险分层

BLOOD
IF23.1
2024-11-050
PRE
NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

NCAM1 (CD56) 作为新诊断急性髓系白血病对标准强化诱导治疗的应答预测指标

BLOOD
IF23.1
2024-11-050
PRE
Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation

滤泡性淋巴瘤的造血细胞移植和细胞治疗的临床实践建议: 代表美国移植和细胞治疗学会和欧洲血液和骨髓移植学会的合作努力

2024-09-012
OAAI